Phase 2, Randomized, Placebo-controlled Trial to Evaluate the Safety and Effect on Post-HIV Acquisition Viremia of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Transgender Women, Who Have Sex With Men.

Trial Profile

Phase 2, Randomized, Placebo-controlled Trial to Evaluate the Safety and Effect on Post-HIV Acquisition Viremia of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Transgender Women, Who Have Sex With Men.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA016-00-VP (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2013 Interim results published National Institute of Allergy and Infectious Diseases (NIAID) media release.
    • 25 Apr 2013 Status changed from recruiting to discontinued, according to National Institute of Allergy and Infectious Diseases (NIAID) media release.
    • 17 Sep 2012 Planned number of patients changed from 2200 to 2500.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top